secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001570562-23-000119
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus signs exclusive deal with Symatese for four dermal fillers in Europe; issues 610,000 shares
--------------------------------------------------------------------------------

- Exclusive rights to distribute Lift, Smooth, Sculpt, and Lips fillers under Estyme® brand in 50 European countries.
- Consideration includes 610,000 common shares to Symatese and up to €3.1M in milestone payments.
- European regulatory approvals expected H2 2024; commercialization targeted for 2025.
- No material impact on 2025 profitability target; company to pre-announce Q4/FY 2023 results and 2024 guidance in January.
- Evolus licenses Nuceiva® to Symatese for France; sub-licenses Estyme® distribution in France to Symatese subsidiary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056223000119/0001570562-23-000119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056223000119/eols-20231220.htm
  HTML page:      https://secwatch.observer/filing/0001570562-23-000119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer